Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.

Saved in:
Bibliographic Details
Title: Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Authors: Brunsvig PF; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Guren TK; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Nyakas M; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Steinfeldt-Reisse CH; Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway., Rasch W; Ultimovacs ASA, Oslo, Norway., Kyte JA; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Juul HV; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Aamdal S; Ultimovacs ASA, Oslo, Norway., Gaudernack G; Ultimovacs ASA, Oslo, Norway., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.
Source: Frontiers in immunology [Front Immunol] 2020 Nov 26; Vol. 11, pp. 572172. Date of Electronic Publication: 2020 Nov 26 (Print Publication: 2020).
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33324397
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Brunsvig+PF%22">Brunsvig PF</searchLink>; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Guren+TK%22">Guren TK</searchLink>; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Nyakas+M%22">Nyakas M</searchLink>; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Steinfeldt-Reisse+CH%22">Steinfeldt-Reisse CH</searchLink>; Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Rasch+W%22">Rasch W</searchLink>; Ultimovacs ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Kyte+JA%22">Kyte JA</searchLink>; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Juul+HV%22">Juul HV</searchLink>; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Aamdal+S%22">Aamdal S</searchLink>; Ultimovacs ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Gaudernack+G%22">Gaudernack G</searchLink>; Ultimovacs ASA, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Inderberg+EM%22">Inderberg EM</searchLink>; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2020 Nov 26; Vol. 11, pp. 572172. <i>Date of Electronic Publication: </i>2020 Nov 26 (<i>Print Publication: </i>2020).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33324397
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2020.572172
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 572172
    Titles:
      – TitleFull: Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brunsvig PF
      – PersonEntity:
          Name:
            NameFull: Guren TK
      – PersonEntity:
          Name:
            NameFull: Nyakas M
      – PersonEntity:
          Name:
            NameFull: Steinfeldt-Reisse CH
      – PersonEntity:
          Name:
            NameFull: Rasch W
      – PersonEntity:
          Name:
            NameFull: Kyte JA
      – PersonEntity:
          Name:
            NameFull: Juul HV
      – PersonEntity:
          Name:
            NameFull: Aamdal S
      – PersonEntity:
          Name:
            NameFull: Gaudernack G
      – PersonEntity:
          Name:
            NameFull: Inderberg EM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 11
              Text: 2020 Nov 26
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 11
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1